T-DM1 Dosing and Dilution Protocol
The recommended dose of trastuzumab emtansine (T-DM1) is 3.6 mg/kg administered intravenously every 21 days (3-week cycles). 1
Standard Dosing Regimen
Weight-based dosing:
- 3.6 mg/kg IV every 3 weeks is the established standard dose across all approved indications 1
- This dosing was validated in multiple phase III trials (NSABP B31, NCCTG N9831, HERA, BCIRG006) and has become the global standard 2
The pharmacokinetic profile supports this dosing schedule, with:
- Mean terminal half-life of 3.8 ± 1.0 days 3
- Dose-proportional exposure at doses ≥1.2 mg/kg 4
- Consistent PK parameters across Western, Asian, Japanese, and Chinese populations 3, 5
Alternative Dosing Schedule
While weekly dosing at 2.4 mg/kg was evaluated in phase I studies and showed antitumor activity with good tolerability 4, the every-3-week schedule at 3.6 mg/kg remains the FDA-approved and guideline-recommended regimen for clinical practice.
Administration Protocol
Intravenous infusion specifications:
- Administer as an IV infusion over 30-90 minutes
- Do NOT administer as IV push or bolus
- Use a 0.2 or 0.22 micron in-line polyethersulfone (PES) filter
Reconstitution and dilution:
- Reconstitute each vial with sterile water for injection
- After reconstitution, immediately dilute in 250 mL of 0.9% Sodium Chloride Injection
- Do NOT use dextrose (5%) solution
- Gently invert the bag to mix; do not shake
Special Population Considerations
Hepatic impairment:
- Patients with mild to moderate hepatic impairment showed faster T-DM1 clearance at cycle 1 (1.8-fold and 4.0-fold, respectively) 6
- However, after repeated dosing (cycle 3), exposure normalized to levels comparable with normal hepatic function 6
- No dose adjustment is required, but monitor closely for toxicity
Obesity:
- Use actual body weight for dosing calculations 7
- Obese patients experience significantly higher rates of treatment modifications (45% vs 25%, p=0.024) and dose delays (36% vs 16%, p=0.011) compared to non-obese patients 7
- Monitor obese patients more closely for thrombocytopenia, hepatotoxicity, and peripheral neuropathy
Critical Safety Monitoring
Mandatory dose modifications for:
- Thrombocytopenia: Most common grade 3-4 adverse event (45.5% in Chinese patients) 3; withhold for platelet count <50,000/mm³
- Hepatotoxicity: Grade 3-4 AST/ALT elevations require dose reduction or discontinuation 5, 8
- Left ventricular dysfunction: Monitor LVEF before each dose; discontinue if LVEF drops significantly
- Peripheral neuropathy: Dose delays may be needed for grade 3-4 events 8
Common Pitfalls to Avoid
- Do not cap the dose at an arbitrary maximum—use full weight-based dosing even in obese patients, but monitor more intensively 7
- Do not use dextrose solutions for dilution—only normal saline is compatible
- Do not extend treatment beyond 52 weeks in the adjuvant setting—longer duration (2 years) showed no additional benefit 2
- Do not overlook transient hepatic impairment effects—clearance normalizes by cycle 3 6
The 3.6 mg/kg every 3 weeks dosing has been validated across diverse populations and clinical settings, with consistent pharmacokinetics supporting this as the definitive standard regimen 1, 3, 5.